EMA Authorised: Oxervate (recombinant human nerve growth factor) — Dompe' Farmaceutici S.p.A.

View source ↗

Summary

The EMA authorised Oxervate (cenegermin), a recombinant human nerve growth factor, for keratitis, with orphan designation and accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratitis

Drugs mentioned

• Oxervate (cenegermin)

Snippet

Status: Authorised. Therapeutic area: Keratitis. MAH: Dompe' Farmaceutici S.p.A.. Decision date: 23/10/2024. Orphan medicine. Accelerated assessment